The standardization of C-peptide assays is highly desirable objective. Our groups have employed the use of a Certified Reference Material (CRM) to calibrate their respective measurement procedures and comparison studies have demonstrated good agreement between the two laboratories [Figure]. Although it was the original choice, The National Metrology Institute of Japan (NMIJ) CRM has not always been available. However, a new material from Cerilliant (C-161-0.1ML) proved equally well defined. Both materials include known amounts of pure C-peptide and small amounts of deamidated and pyroglutamated forms (Cerilliant Lot# FN0422195.6% modified; NMIJ CRM 6901-b, Lot# 058 1.9% modified) . The C-peptide CRMs from Cerilliant and from NMIJ behave identically when the mass concentration of the unmodified C-peptide is used to assign calibrator concentrations. To avoid potential bias, we conclude that the mass concentration of unmodified C-peptide (not the mass concentration of total C-peptide) in CRM should be used when making calibrators for mass spectrometry C-peptide assays to achieve comparable patient results. Variation in the relative amount of modified C-peptide is an obstacle to standardization, especially when comparing mass spectrometry-based assays with immunoassays, which use total C-peptide for calibration.


Z.Wu: Employee; Quest Diagnostics. K.Kabytaev: None. J.Mu: None. S.Connolly: None. M.J.Mcphaul: Employee; Quest Diagnostics. R.R.Little: None.


NIH/NIDDK (1UC4DK096587-01)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at